COVID-19 Vaccines Likely Won't Impact General Public Until Summer 2021, JPMorgan Analyst Says - (Fidelity via NewsPoints Desk)

  • JPMorgan analyst Cory Kasimov said that while Pfizer and BioNTech's new COVID-19 vaccine is good news in the battle against the pandemic, the general public should not expect vaccines to have a major impact on their lives until next summer, as reported in Fidelity.

  • The companies recently reported early Phase III trial data indicating that the vaccine candidate was more than 90% effective in preventing COVID-19.

  • Kasimov said in a posting that while there still are some unanswered questions about the vaccine pertaining to side effects and how well it works in various populations, a 90% efficacy rate is a "best case outcome."

  • The analyst noted "there's a lot we still need to learn, but having a vaccine that works-the first of over 200 that are in development-and having it work so well is a great accomplishment and the clearest sign yet that life is going to get back to the new normal in the not too distant future."

  • Meanwhile, Kasimov said data on Moderna's vaccine is expected in the next two or three weeks, followed by Phase III results on vaccines being developed by Johnson & Johnson and AstraZeneca. Data on additional vaccines should be out during the first half of 2021.

  • "My best guess from a mass vaccination point of view is that we're probably looking towards next summer. Maybe for an absolute best case it's late spring, but I think for your typical individual it's still some ways off," he added.

To read more NewsPoints articles, click here.